Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hongjing I Granule (also known as hongjing-1) is a Traditional Chinese Medicine (TCM) preparation developed by The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine for the treatment of erectile dysfunction (impotence). The formulation is based on the Yiqi Huoxue therapeutic principle, which focuses on replenishing qi and promoting blood circulation to address the underlying pathophysiology of impotence. It has been evaluated in multicenter, randomized, double-blind, placebo-controlled clinical trials to establish its efficacy and safety profile as a potential new Chinese medicine preparation, transitioning from traditional theory to clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hongjing I Granule.